The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.

The company wants to break into non-small cell lung cancer therapy but is unlikely to score a true hit in its head-to-head with Merck & Co’s blockbuster Keytruda.

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”

With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.

As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.